PeptidePedia The community reference

Contributions of AnalyticalAnnie

User contributions·69 logged edits·page 1 of 1

Contributions by AnalyticalAnnie, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 37,940 edits includes activity predating the current log.

  1. 13:40, 17 Jul 2026 (diff | hist) Shanghai Wibson Biotechnology 11,996 ±0 split overlong sentence
  2. 23:28, 24 Jun 2026 (diff | hist) Peptide stability table 6,886 ±0 m rm maintenance tag, addressed
  3. 07:34, 10 Jun 2026 (diff | hist) GL Biochem (Shanghai) 13,879 ±0 hedge overclaim
  4. 18:30, 7 Jun 2026 (diff | hist) Insulin syringe unit conversion 6,290 ±0 fix unit
  5. 04:38, 6 Jun 2026 (diff | hist) Hunan Aslsen Technology 12,103 ±0 add hatnote
  6. 06:06, 4 Jun 2026 (diff | hist) Chinese Peptide Company 12,627 ±0 add PMID
  7. 13:51, 29 May 2026 (diff | hist) Sharps disposal 8,858 +618 add see also
  8. 17:51, 24 May 2026 (diff | hist) Karl Fischer titration 9,318 ±0 reorder sections to follow the class template
  9. 12:31, 18 Apr 2026 (diff | hist) Talk:Karl Fischer titration 1,022 +178 /* Should the mass-balance table give ranges or single figures? */ reply
  10. 15:44, 15 Apr 2026 (diff | hist) Talk:Peptide stability table 885 +304 /* RfC: should the table give a −20 °C default for research powders? */ reply
  11. 12:33, 8 Apr 2026 (diff | hist) Talk:Incretin effect 811 +236 /* Measurement methods: mention the glucagon secretion measurement too? */ new section
  12. 18:21, 7 Apr 2026 (diff | hist) Cold chain 27,220 ±0 add figure
  13. 23:56, 1 Apr 2026 (diff | hist) Multi-dose vial 24,628 ±0 m tag [citation needed]
  14. 13:15, 26 Mar 2026 (diff | hist) Talk:Incretin effect 748 +258 /* Asymmetric loss in T2D — is the GIP figure sourced? */ reply
  15. 11:05, 19 Mar 2026 (diff | hist) Talk:Glucose-dependent insulinotropic polypeptide 537 +244 /* Adipose-tissue mechanism remains speculative */ new section
  16. 15:31, 11 Mar 2026 (diff | hist) Talk:Hubei Jianxiang Bioscience 748 +268 /* Should the peptide-content explanation live here? */ reply
  17. 03:15, 9 Mar 2026 (diff | hist) Glucose-dependent insulinotropic polypeptide 8,265 ±0 promote subsection to section
  18. 12:19, 5 Mar 2026 (diff | hist) Talk:Hunan Aslsen Technology 537 +311 /* Area percent on SARMs */ new section
  19. 09:12, 28 Feb 2026 (diff | hist) Talk:Shanghai ERP Biotechnology 959 +190 /* Endotoxin results: worth a paragraph? */ reply
  20. 09:54, 19 Feb 2026 (diff | hist) Flourishglobal Peptide Biotech 12,100 ±0 update infobox
  21. 09:37, 2 Feb 2026 (diff | hist) Insulin syringe unit conversion 6,290 ±0 split overlong sentence
  22. 10:33, 28 Jan 2026 (diff | hist) Talk:Glucose-dependent insulinotropic polypeptide 1,022 +190 /* Fasting concentration range — should this be in the infobox? */ reply
  23. 13:05, 22 Jan 2026 (diff | hist) Talk:Enteroendocrine L cell 811 +208 /* Should this article cover L-cell-derived peptides beyond GLP-1? */ new section
  24. 21:58, 5 Jan 2026 (diff | hist) Beyond-use date 23,108 ±0 expand §Opened containers
  25. 16:14, 19 Dec 2025 (diff | hist) GL Biochem (Shanghai) 13,879 ±0 ce
  26. 15:07, 16 Dec 2025 (diff | hist) Talk:Guangzhou JEEP Biotechnology 748 +239 /* Method disclosure within one report set */ reply
  27. 17:14, 15 Dec 2025 (diff | hist) Hunan Aslsen Technology 12,103 +186 correct percentage: source reports placebo-adjusted
  28. 10:57, 13 Dec 2025 (diff | hist) Incretin effect 7,358 ±0 add figure
  29. 15:08, 4 Dec 2025 (diff | hist) Talk:Temperature excursion 885 +352 /* Is a community-reported stability observation usable evidence at all? */ reply
  30. 16:03, 27 Nov 2025 (diff | hist) Talk:Shanghai Wibson Biotechnology 748 +270 /* Purity-only certificates: how strongly should we put it? */ reply
  31. 15:44, 6 Nov 2025 (diff | hist) Talk:Bachem Holding (Suzhou) 748 +233 /* Purity without a reference standard */ reply
  32. 09:47, 23 Oct 2025 (diff | hist) Talk:Nantong Guangyuan Chemical 959 +198 /* Warehouse storage interval is a real documentary gap */ reply
  33. 07:49, 14 Oct 2025 (diff | hist) Chinese Peptide Company 12,441 ±0 add citation
  34. 02:45, 10 Oct 2025 (diff | hist) Multi-dose vial 21,761 +276 restructure
  35. 15:41, 8 Oct 2025 (diff | hist) Talk:Chinese Peptide Company 748 +508 /* The water-figure observation — are we praising a supplier? */ reply
  36. 09:55, 21 Sep 2025 (diff | hist) Talk:Lyophilisation 1,096 +214 /* Collapse temperature and Tg-prime are being used interchangeably */ reply
  37. 10:38, 18 Sep 2025 (diff | hist) Tianjin Finder Chemical 10,556 ±0 rm citation to a supplier's own page
  38. 09:21, 9 Sep 2025 (diff | hist) Talk:Peptide stability table 822 +303 /* Sourcing of the reconstituted-stability column */ reply
  39. 20:14, 22 Aug 2025 (diff | hist) Incretin effect 7,134 ±0 fix significant figures — source gives fewer
  40. 11:33, 19 Aug 2025 (diff | hist) Talk:Xi'an Mokemei Biotechnology 537 +285 /* Extract-derived listings need their own treatment */ new section
  41. 11:38, 14 Aug 2025 (diff | hist) Talk:Karl Fischer titration 611 +327 /* Worked example — is the arithmetic order right? */ reply
  42. 09:28, 23 Jul 2025 (diff | hist) Talk:Cold chain 1,096 +264 /* Logger accuracy: is ±0.5 °C a standard or an expectation? */ reply
  43. 01:18, 5 Jul 2025 (diff | hist) Qingdao Saber Technology Pharmaceutical 3,929 +1,443 add DOI
  44. 23:07, 23 Jun 2025 (diff | hist) Nantong Guangyuan Chemical 10,177 ±0 hedge overclaim
  45. 13:42, 17 Jun 2025 (diff | hist) Talk:Wuhan Wansheng Biotechnology 611 +403 /* RfC: does a large report set support any conclusion? */ reply
  46. 15:49, 12 Jun 2025 (diff | hist) Temperature excursion 10,117 ±0 rv addition of price information per PP:VN
  47. 07:16, 12 Jun 2025 (diff | hist) Hunan Aslsen Technology 8,883 +207 m add confidence interval
  48. 17:50, 11 Jun 2025 (diff | hist) Karl Fischer titration 7,949 ±0 add confidence interval
  49. 10:02, 11 Jun 2025 (diff | hist) Talk:Glucagon-like peptide-1 1,159 +247 /* Should the fasting concentration range be in the infobox? */ reply
  50. 14:22, 10 Jun 2025 (diff | hist) Talk:Zhuhai Kerui Biotechnology 611 +445 /* Method disclosure: are we writing an endorsement? */ reply
  51. 03:01, 18 May 2025 (diff | hist) Lyophilisation 21,545 ±0 expand §Primary drying
  52. 08:31, 16 May 2025 (diff | hist) Talk:Reconstitution calculator 1,170 +90 /* Should the default vial mass be the gross or net figure? */ reply
  53. 13:22, 14 May 2025 (diff | hist) Talk:Reconstitution calculator 537 +429 /* Should the default vial mass be the gross or net figure? */ new section
  54. 15:18, 7 May 2025 (diff | hist) ChinaPeptides 7,820 +522 add category
  55. 02:25, 25 Mar 2025 (diff | hist) GL Biochem (Shanghai) 11,663 ±0 cite the trial publication rather than the press release
  56. 13:57, 18 Mar 2025 (diff | hist) Enteroendocrine L cell 4,619 ±0 fix category — parent was wrong
  57. 14:47, 12 Feb 2025 (diff | hist) Karl Fischer titration 6,559 +538 m copyedit
  58. 00:37, 22 Jan 2025 (diff | hist) Insulin syringe unit conversion 3,086 ±0 attribute range as a review estimate per talk
  59. 18:44, 12 Jan 2025 (diff | hist) Peptide stability table 1,664 ±0 m copyedit
  60. 08:00, 6 Jan 2025 (diff | hist) Peptide stability table 1,664 ±0 tag [citation needed]
  61. 15:15, 5 Dec 2024 (diff | hist) Sangon Biotech 1,705 ±0 fix arithmetic in worked example
  62. 06:17, 14 Nov 2024 (diff | hist) Wuhan Wansheng Biotechnology 5,929 ±0 m expand §Independent testing record
  63. 09:17, 7 Oct 2024 (diff | hist) Nantong Guangyuan Chemical 4,987 ±0 rv — see talk
  64. 03:21, 10 Sep 2024 (diff | hist) Nantong Guangyuan Chemical 2,787 ±0 m typo
  65. 04:38, 2 Sep 2024 (diff | hist) Karl Fischer titration 4,136 +532 m convert list to prose
  66. 14:38, 27 Aug 2024 (diff | hist) Talk:Guangzhou JEEP Biotechnology 611 +240 /* Concentrated catalogue makes the report set more interpretable */ reply
  67. 20:09, 24 Aug 2024 (diff | hist) Nantong Guangyuan Chemical 2,787 ±0 rm unsourced claim per PP:V
  68. 19:25, 20 Jul 2024 (diff | hist) WuXi TIDES 1,770 ±0 rv unexplained removal of sourced content
  69. 13:36, 15 Jun 2024 (diff | hist) Incretin effect 1,841 ±0 undo good-faith edit: the source does not say this